Compare TGL & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | MBRX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.4M |
| IPO Year | 2022 | 2016 |
| Metric | TGL | MBRX |
|---|---|---|
| Price | $0.25 | $9.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $240.00 |
| AVG Volume (30 Days) | ★ 8.9M | 412.0K |
| Earning Date | 10-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,169,784.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 121.83 | N/A |
| 52 Week Low | $0.19 | $0.16 |
| 52 Week High | $587.80 | $15.75 |
| Indicator | TGL | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 25.57 | 92.25 |
| Support Level | $0.19 | $2.12 |
| Resistance Level | $3.30 | N/A |
| Average True Range (ATR) | 0.19 | 0.45 |
| MACD | 0.02 | 0.82 |
| Stochastic Oscillator | 4.94 | 97.36 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.